Clinical-stage pharmaceutical company Altesa BioSciences Inc announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for vapendavir for the treatment of rhinovirus infections in people living with Chronic obstructive pulmonary disease (COPD).
This enables the company to commence clinical trials in the United States for this patient population.
Vapendavir is taken orally in pill form and is a broad-spectrum antiviral medicine that prevents the virus from entering human cells and replicating. According to Altesa, it demonstrates potent activity across 97% of rhinoviruses and other respiratory enteroviruses.
Altesa has exclusive global rights to develop, manufacture and commercialise vapendavir.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval